Small Molecule Targeting Inflammation without Immunosuppression

SynAct Pharma is focused on developing innovative therapies that leverage the melanocortin system to address inflammatory and autoimmune diseases, particularly rheumatoid arthritis (RA). Their lead drug candidate, resomelagon (AP1189), is a selective melanocortin agonist designed to stimulate specific melanocortin receptors (MC1R and MC3R) while avoiding the activation of MC2R, which is associated with cortisol release and potential side effects. This targeted approach aims to resolve excessive inflammation without suppressing the immune system, thereby minimizing the risks of serious safety issues commonly associated with traditional anti-inflammatory treatments. Resomelagon is currently being evaluated in various clinical trials for its efficacy and safety in treating RA, idiopathic membranous nephropathy, and respiratory insufficiency due to viral infections.

The clinical development of resomelagon has shown promising results, particularly in its ability to provide a quick onset of action and a favorable safety profile. In Phase 2 studies, resomelagon demonstrated significant reductions in disease activity among RA patients, with a notable percentage achieving clinically meaningful responses. The drug's oral formulation allows for convenient once-daily dosing, and it has been well tolerated in clinical settings, with no observed immunosuppression. SynAct Pharma is also exploring the potential of resomelagon in patients who have not responded adequately to first-line disease-modifying anti-rheumatic drugs (DMARDs), indicating its versatility and potential to fill unmet medical needs in the treatment of chronic inflammatory conditions.

Sweden

SynAct Pharma is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral melanocortin receptor agonists for the treatment of inflammatory diseases. For more information, visit https://synactpharma.com/en/

SynAct Pharma

Company Details